Literature DB >> 23230408

Commentary.

Daryl R Fourney1.   

Abstract

Entities:  

Year:  2011        PMID: 23230408      PMCID: PMC3506151          DOI: 10.1055/s-0032-1330858

Source DB:  PubMed          Journal:  Evid Based Spine Care J        ISSN: 1663-7976


× No keyword cloud information.
Hypokalaemic paralysis secondary to thiazide diuretic abuse: an unexpected outcome for cauda equina syndrome Cawley et al describe an interesting case of progressive leg weakness and urinary retention caused by severe hypokalemia. The neurological presentation somewhat mimicked cauda equina syndrome, although there was no back or leg pain and no saddle anesthesia. On a cursory review of the literature, I could find no other cases of cauda equina syndrome caused by thiazide-induced hypokalemia. However, there is a recent report1 of a patient with lower extremity weakness, sensory disturbance, and intermittent urinary incontinence from Gitelman syndrome, which is a rare inherited defect in the distal convoluted tubule of the kidneys that manifests as hypochloremic metabolic alkalosis, hypokalemia, and hypocalciuria. People with Gitelman syndrome present with a metabolic profile almost identical to those treated with thiazide diuretics.2 It is important to remember that cauda equina syndrome has a wide differential diagnosis including compressive, ischemic, and/or inflammatory neuropathy of multiple lumbar and sacral nerve roots.3 The literature is rife with examples of unusual organic explanations for this clinical presentation, including transverse myelitis, vasculitis, spinal dural arteriovenous fistula, spinal ischemic stroke, inflammatory polyradiculopathy (autoimmune or infectious), and meningeal carcinomatosis (lymphomatous or metastatic).4 Although a structural cause, such as a large lumbar disc herniation, is important to rule out, Rooney et al5 reported that 48% of patients seen in the emergency department for cauda equina syndrome turned out to have no obvious structural abnormality on magnetic resonance imaging. While some patients had an alternate organic cause, most cases were “non-organic” (ie, functional) in nature. The authors have provided a valuable contribution to the literature, not only because they made an astute diagnosis, saving a patient who was in a “pre-arrest” state to a full recovery but also by adding to the broader differential diagnosis of cauda equina syndrome.

Editorial Perspective

EBSJ thanks the authors for providing this fascinating case and reminding us of the bewildering variety of conditions that may present as spinal disorder. The commentary provided by Dr. Fourney underscores the rarity of this disorder and adds another variant to electrophysiological imbalance mimicking neurologic dysfunction with the description of Gitelman syndrome. While there remains strong hope for increasing cost efficiency in healthcare by more widespread use of care pathways in common conditions such as low back pain, cases like these remind us that there is no substitute for practicing good medicine when encountering each individual patient.
  5 in total

1.  Cauda equina syndrome: factors affecting long-term functional and sphincteric outcome.

Authors:  Michael J H McCarthy; Caspar E W Aylott; Michael P Grevitt; James Hegarty
Journal:  Spine (Phila Pa 1976)       Date:  2007-01-15       Impact factor: 3.468

2.  Timing of surgery in cauda equina syndrome with urinary retention: meta-analysis of observational studies.

Authors:  W Bradford DeLong; Nayak Polissar; Blazej Neradilek
Journal:  J Neurosurg Spine       Date:  2008-04

3.  Gitelman's syndrome: a rare presentation mimicking cauda equina syndrome.

Authors:  C S Quinlan; J C Walsh; A-M Moran; C Moran; S K O'Rourke
Journal:  J Bone Joint Surg Br       Date:  2011-02

Review 4.  Salt handling and hypertension.

Authors:  Kevin M O'Shaughnessy; Fiona E Karet
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

5.  Cauda equina syndrome with normal MR imaging.

Authors:  Alasdair Rooney; Patrick F Statham; Jon Stone
Journal:  J Neurol       Date:  2009-02-25       Impact factor: 4.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.